多剤耐性菌の世界市場レポート 2024年

多剤耐性菌市場規模は近年力強く成長しています。2023年の118億6,000万米ドルから2024年には126億1,000万米ドルに、CAGR6.4％で拡大します。歴史的な期間の成長は、抗生物質耐性の危機、創薬の進歩、規制上の優遇措置、公衆衛生への取り組みに起因しています。

感染症の有病率の上昇は、将来の多剤耐性菌市場の成長を促進すると予想されます。感染症には、細菌、ウイルス、真菌、寄生虫などの有害な微生物によって引き起こされる病気が含まれます。多剤耐性菌は、従来の抗生物質では治療が困難な感染症を引き起こす可能性があるため、感染症と密接な関係があります。これらの細菌は複数の抗生物質に対する耐性を獲得しており、細菌感染症に一般的に使用される薬剤に対する感受性を低下させています。例えば、オーストラリアの政府機関であるオーストラリア保健福祉研究所（AIHW）のデータによると、オーストラリアで届出可能な感染症の数は、2020年の289,013件から2021年には701,820件に増加することが明らかになった。従って、感染症の流行拡大は多剤耐性菌市場の原動力となると思われます。

2023年の多剤耐性菌市場では北米が最大地域でした。多剤耐性菌レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の多剤耐性菌市場、疾患別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 尿路感染
• 腹腔内感染症
• 血流感染症
• クロストリジウム・ディフィシル感染症
• 急性細菌性皮膚および皮膚構造感染症
• 院内感染性細菌性肺炎
• 後天性細菌性肺炎
• その他
• 世界の多剤耐性菌市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• オキサゾリジノン
• リポ糖ペプチド
• テトラサイクリン系
• セファロスポリン類
• 併用療法
• その他
• 世界の多剤耐性菌市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 非経口
• その他
• 世界の多剤耐性菌市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 専門クリニック
• 在宅ケア
• その他

第7章 地域および国の分析

• 世界の多剤耐性菌市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の多剤耐性菌市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多剤耐性菌市場の競合情勢
• 多剤耐性菌市場の企業プロファイル
  • Pfizer Inc.
  • Johnson And Johnson Private Limited
  • F. Hoffmann-La Roche Ltd.
  • Merck And Co. Inc.
  • Bayer AG

第31章 その他の主要および革新的な企業

• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Dr. Reddy's Laboratories Ltd.
• Lupin Pharmaceuticals Inc.
• BioMarin Pharmaceuticals Inc.
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

“Multidrug Resistant Bacteria Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multidrug resistant bacteria market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multidrug resistant bacteria? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The multidrug resistant bacteria market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Disease: Urinary Tract Infection; Intra-Abdominal Infections; Blood Stream Infections; Clostridium Difficile Infections; Acute Bacterial Skin And Skin Structure Infections; Hospital Acquired Bacterial Pneumonia; Acquired Bacterial Pneumonia; Other Diseases
• 2) By Drug Class: Oxazolidinones; Lipoglycopeptides; Tetracyclines; Cephalosporins; Combination Therapies; Other Drug Classes
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck And Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Multidrug-resistant bacteria are strains of bacteria that have developed resistance to multiple classes of antibiotics, rendering them no longer susceptible to the effects of several different antibiotics that are typically effective in treating bacterial infections. These resilient bacteria are often found in hospital and medical care settings, where antibiotics are sometimes overused or used unnecessarily.

Various diseases are caused by multidrug-resistant bacteria, including urinary tract infections, intra-abdominal infections, bloodstream infections, Clostridium difficile infections, acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia, among others. Urinary tract infections, for example, can affect different parts of the urinary system, such as the kidneys, bladder, and ureters. The treatment of these diseases involves the use of various drugs, including oxyazolidinones, lipoglycopeptides, tetracyclines, cephalosporins, combination therapies, and more, administered through oral, parenteral, and other routes. These treatments are provided to patients in various healthcare settings, including hospitals, specialty clinics, homecare, and others.

The multidrug-resistant bacteria market research report is one of a series of new reports from The Business Research Company that provides multidrug-resistant bacteria market statistics, including multidrug-resistant bacteria industry global market size, regional shares, competitors with a multidrug-resistant bacteria market share, detailed multidrug-resistant bacteria market segments, market trends and opportunities and any further data you may need to thrive in the multidrug-resistant bacteria industry. This multidrug-resistant bacteria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The multidrug resistant bacteria market size has grown strongly in recent years. It will grow from $11.86 billion in 2023 to $12.61 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to antibiotic resistance crisis, advancements in drug discovery, regulatory incentives, public health initiatives.

The multidrug resistant bacteria market size is expected to see strong growth in the next few years. It will grow to $16.22 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to antibiotic stewardship programs, global spread of resistance, phage therapy and alternative treatments, public and private investment. Major trends in the forecast period include precision medicine for infectious diseases, combination therapies, continuous surveillance and monitoring, global collaboration.

The rising prevalence of infectious diseases is expected to drive the growth of the multidrug-resistant bacteria market in the future. Infectious diseases encompass illnesses caused by harmful microorganisms like bacteria, viruses, fungi, or parasites. Multidrug-resistant bacteria are closely linked to infectious diseases because they can lead to infections that are challenging to treat with conventional antibiotics. These bacteria have developed resistance to multiple antibiotics, reducing their susceptibility to commonly used medications for bacterial infections. For instance, data from the Australian Institute of Health and Welfare (AIHW), an Australian government agency, revealed that the number of notifiable infectious diseases in Australia increased from 289,013 in 2020 to 701,820 in 2021. Therefore, the growing prevalence of infectious diseases will be a driving force behind the multidrug-resistant bacteria market.

The complexity of infections is impeding the growth of the multidrug-resistant bacteria market during the forecast period. Infections caused by multidrug-resistant (MDR) bacteria can be more severe and challenging to treat compared to infections caused by susceptible bacteria. This complexity can result in extended hospital stays, increased healthcare costs, and poorer patient outcomes. For instance, a report published in the Lancet, a UK-based peer-reviewed journal, in February 2022 suggested that by 2050, antimicrobial resistance (AMR) might be responsible for up to 10 million annual deaths. Therefore, the impact of infection complexity is presenting a hindrance to the growth of the multidrug-resistant bacteria market.

Major companies operating in the multidrug-resistant bacteria market are placing a strong emphasis on the development of innovative drugs and securing approvals to address the needs of a new segment of consumers. The approval of drugs designed to combat multidrug-resistant bacteria is crucial in the ongoing fight against antibiotic resistance. For example, in May 2023, Entasis Therapeutics Inc., a US-based biotech company, achieved approval from the Food and Drug Administration (FDA) for Xacduor, a combination antibiotic formulated to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VAP) caused by acinetobacter baumannii, a particularly challenging pathogen to treat. Xacduor consists of a combination of ceftolozane and tedizolid phosphate. Ceftolozane is a cephalosporin antibiotic, while tedizolid phosphate belongs to the oxazolidinone class of antibiotics. This approval provides a new treatment option for patients infected with Acinetobacter baumannii who have not responded to other therapies. It can be administered via injection and combines the antibiotic beta-lactam sulbactam with the broad-spectrum beta-lactamase inhibitor durlobactam, reducing acinetobacter resistance and enabling the antibiotic to effectively combat the infection.

In July 2022, Innoviva Inc., a US-based pharmaceutical company, acquired Entasis Therapeutics Inc. for an undisclosed amount. This strategic acquisition expands Innoviva's portfolio, encompassing potential first- and best-in-class medications for the treatment of multidrug-resistant gram-negative bacteria, including the lead asset SUL-DUR. Entasis Therapeutics Inc. is a US-based biotech company specializing in the development of antibacterial therapeutics aimed at addressing serious infections caused by multidrug-resistant bacteria.

Major players in the multidrug resistant bacteria market are Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Lupin Pharmaceuticals Inc., BioMarin Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories, Wockhardt Ltd., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Theravance Biopharma Inc., Melinta Therapeutics Inc., Armata Pharmaceuticals Inc., Tetraphase Pharmaceuticals Inc.

North America was the largest region in the multidrug-resistant bacteria market in 2023. The regions covered in multidrug-resistant bacteria report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the multidrug-resistant bacteria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multidrug-resistant bacteria market consists of revenues earned by entities by providing services such as infection diagnosis and combination therapy, surgery and antimicrobial stewardship. The market value includes the value of related goods sold by the service provider or included within the service offering. The multidrug-resistant bacteria market also consists of sales of colistin, polymyxins, aminoglycosides, antibiotic synergy kits, monoclonal antibodies and vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Multidrug Resistant Bacteria Market Characteristics

3. Multidrug Resistant Bacteria Market Trends And Strategies

4. Multidrug Resistant Bacteria Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Multidrug Resistant Bacteria Market Size and Growth

• 5.1. Global Multidrug Resistant Bacteria Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Multidrug Resistant Bacteria Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Multidrug Resistant Bacteria Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Multidrug Resistant Bacteria Market Segmentation

• 6.1. Global Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Urinary Tract Infection
• Intra-Abdominal Infections
• Blood Stream Infections
• Clostridium Difficile Infections
• Acute Bacterial Skin And Skin Structure Infections
• Hospital Acquired Bacterial Pneumonia
• Acquired Bacterial Pneumonia
• Other Diseases
• 6.2. Global Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oxazolidinones
• Lipoglycopeptides
• Tetracyclines
• Cephalosporins
• Combination Therapies
• Other Drug Classes
• 6.3. Global Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users

7. Multidrug Resistant Bacteria Market Regional And Country Analysis

• 7.1. Global Multidrug Resistant Bacteria Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Multidrug Resistant Bacteria Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Multidrug Resistant Bacteria Market

• 8.1. Asia-Pacific Multidrug Resistant Bacteria Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Multidrug Resistant Bacteria Market

• 9.1. China Multidrug Resistant Bacteria Market Overview
• 9.2. China Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Multidrug Resistant Bacteria Market

• 10.1. India Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Multidrug Resistant Bacteria Market

• 11.1. Japan Multidrug Resistant Bacteria Market Overview
• 11.2. Japan Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Multidrug Resistant Bacteria Market

• 12.1. Australia Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Multidrug Resistant Bacteria Market

• 13.1. Indonesia Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Multidrug Resistant Bacteria Market

• 14.1. South Korea Multidrug Resistant Bacteria Market Overview
• 14.2. South Korea Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Multidrug Resistant Bacteria Market

• 15.1. Western Europe Multidrug Resistant Bacteria Market Overview
• 15.2. Western Europe Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Multidrug Resistant Bacteria Market

• 16.1. UK Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Multidrug Resistant Bacteria Market

• 17.1. Germany Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Multidrug Resistant Bacteria Market

• 18.1. France Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Multidrug Resistant Bacteria Market

• 19.1. Italy Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Multidrug Resistant Bacteria Market

• 20.1. Spain Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Multidrug Resistant Bacteria Market

• 21.1. Eastern Europe Multidrug Resistant Bacteria Market Overview
• 21.2. Eastern Europe Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Multidrug Resistant Bacteria Market

• 22.1. Russia Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Multidrug Resistant Bacteria Market

• 23.1. North America Multidrug Resistant Bacteria Market Overview
• 23.2. North America Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Multidrug Resistant Bacteria Market

• 24.1. USA Multidrug Resistant Bacteria Market Overview
• 24.2. USA Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Multidrug Resistant Bacteria Market

• 25.1. Canada Multidrug Resistant Bacteria Market Overview
• 25.2. Canada Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Multidrug Resistant Bacteria Market

• 26.1. South America Multidrug Resistant Bacteria Market Overview
• 26.2. South America Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Multidrug Resistant Bacteria Market

• 27.1. Brazil Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Multidrug Resistant Bacteria Market

• 28.1. Middle East Multidrug Resistant Bacteria Market Overview
• 28.2. Middle East Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Multidrug Resistant Bacteria Market

• 29.1. Africa Multidrug Resistant Bacteria Market Overview
• 29.2. Africa Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Multidrug Resistant Bacteria Market Competitive Landscape And Company Profiles

• 30.1. Multidrug Resistant Bacteria Market Competitive Landscape
• 30.2. Multidrug Resistant Bacteria Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson And Johnson Private Limited
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck And Co. Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bayer AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Multidrug Resistant Bacteria Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca plc
• 31.5. GlaxoSmithKline plc
• 31.6. Eli Lilly and Company
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Gilead Sciences Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Mylan N.V.
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Lupin Pharmaceuticals Inc.
• 31.13. BioMarin Pharmaceuticals Inc.
• 31.14. Zydus Lifesciences Limited
• 31.15. Glenmark Pharmaceuticals Ltd.

32. Global Multidrug Resistant Bacteria Market Competitive Benchmarking

33. Global Multidrug Resistant Bacteria Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Multidrug Resistant Bacteria Market

35. Multidrug Resistant Bacteria Market Future Outlook and Potential Analysis

• 35.1 Multidrug Resistant Bacteria Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Multidrug Resistant Bacteria Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Multidrug Resistant Bacteria Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer